STOCK TITAN

Kory Wentworth sells TRDA shares via 10b5-1 plan (TRDA) reported to SEC

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Kory Wentworth reported planned sales of Common Stock under a 10b5-1 plan. The filing lists three trades: 03/02/2026 sale of 2,939 shares for $34,262.57, 03/03/2026 sale of 5,712 shares for $67,152.56, and 03/04/2026 sale of 7,988 shares for $97,892.14. The broker listed is Morgan Stanley Smith Barney LLC. The filing also records securities listed as previously exercised stock options (9,395 shares, 06/29/2023) and restricted stock units (7,082 shares, 09/01/2025).

Positive

  • None.

Negative

  • None.

Insights

Filed 10b5-1 sales were executed across three days by the reporting person.

Kory Wentworth sold common shares via a 10b5-1 plan on 03/02/2026, 03/03/2026, and 03/04/2026, with proceeds shown as $34,262.57, $67,152.56, and $97,892.14 respectively. The sales are reported through Morgan Stanley Smith Barney LLC.

These entries follow a standard scheduled-plan disclosure pattern; the filing lists related equity sources including previously exercised stock options (9,395 shares) and restricted stock units (7,082 shares). Timing and cash-flow treatment are disclosed by trade dates and proceeds; additional plan documentation would specify whether trades were pre-scheduled or discretionary.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did Kory Wentworth sell in the TRDA Form 144 filing?

Kory Wentworth sold common shares under a 10b5-1 plan on three dates for reported proceeds. The filing lists 2,939 shares on 03/02/2026 ($34,262.57), 5,712 shares on 03/03/2026 ($67,152.56), and 7,988 shares on 03/04/2026 ($97,892.14).

Which broker handled the transactions in the TRDA Form 144?

The broker shown is Morgan Stanley Smith Barney LLC. The filing header lists the broker's address as 1 New York Plaza, 8th Floor, New York, NY 10004, indicating the intermediary used for the reported sales.

Are the reported sales linked to specific equity sources?

Yes. The filing records securities tied to earlier awards: previously exercised stock options of 9,395 shares dated 06/29/2023 and restricted stock units of 7,082 shares dated 09/01/2025, listed as securities to be sold.

Were the sales executed under a 10b5-1 plan or open-market trades?

The filing identifies the trades as 10b5-1 Sales. Each trade row is labeled accordingly for 03/02/2026, 03/03/2026, and 03/04/2026, indicating scheduled-plan sales rather than discretionary open-market notifications.

How much cash did the reported sales generate in total (per the filing)?

The filing reports proceeds for each trade separately: $34,262.57, $67,152.56, and $97,892.14. These figures are shown next to the respective trade dates in the filing.
Entrada Therapeutics, Inc.

NASDAQ:TRDA

View TRDA Stock Overview

TRDA Rankings

TRDA Latest News

TRDA Latest SEC Filings

TRDA Stock Data

471.28M
32.67M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON